Rep. Marjorie Taylor Greene calls for yanking FDA approval of COVID-19 vaccines, says that "COVID-19 vaccines are causing ...

FDA approved Alnylam's Amvuttra for ... Also Read: Alnylam’s Concedes Its Patent Infringement Case Against Moderna’s COVID-19 Vaccine This approval is based on the HELIOS-B Phase 3 clinical ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said.

Moderna is advancing its oncology portfolio with individualized neoantigen therapy (INT) and T-cell engagers. The company anticipates data readouts for melanoma and CMV vaccine trials in 2026 and ...

This page is no longer being updated and reflects the status of ... concept to approval in 1967. Developing messenger RNA vaccines such as the Pfizer-BioNTech and Moderna candidates has been ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

Fors Marsh Group used demographic data, like age, ethnicity, parenting status ... The FDA repeated this message in issuing its emergency use authorizations for the Moderna vaccine on Dec. 18 ...